According to World Health Organization data, endometriosis affects about 10% of reproductive-age females globally. That already makes endometriosis a wildly underresearched and underfunded disease in relation to its prevalence. Plus, Rama Kommagani thinks even 10% is an underestimation. “Diagnosis is very underreported, particularly in low- and middle-income countries,” Kommagani, who is an associate professor of pathology at Baylor College of Medicine, told BioWorld. Read More
Glioblastoma multiforme (GBM) recurs in most patients despite the aggressive therapies they receive. Novel advances allow the development of targeted therapies to treat tumors of the brain. Researchers from the Johns Hopkins School of Medicine have applied bioinformatics plus forward thinking on microRNA biology to advance targeted therapies for GBM. Read More
Avacta Group plc has expanded its pipeline of Precision-enabled drug conjugates with the addition of two novel preclinical oncology assets, AVA-6103 and AVA-7100. The company’s peptide-drug conjugates (PDCs) comprise a payload linked to the Precision peptide, which is cleaved only within the tumor by the action of fibroblast activation protein (FAP). Read More
Exscientia plc has announced progression of two additional discovery programs within its collaboration with Sanofi. Both lead compounds have met the product profile requirements, set by both parties, to enable a transition to the lead optimization phase within the collaboration. Read More
Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders. Read More
Researchers from Xencor Inc. presented the discovery and preclinical characterization of XmAb-942, a novel high-affinity anti-TL1A monoclonal antibody (MAb) being developed for the treatment of inflammatory bowel disease (IBD). Read More
Claudin-6 (CLDN6) is a tight junction protein that has been found to be up-regulated in around 20 different types of cancer, among them ovarian, endometrial and germ cell tumors. Conventional T-cell engagers (TCEs), although effective, may be improved with costimulation to overcome T-cell exhaustion due to CDE3 stimulation alone. Read More
Scientists at Atmosr SAS and Medetia SAS have synthesized adenine derivatives acting as heat shock protein 90 (HSP90) inhibitors reported to be useful for the treatment of cancer, neurodegenerative diseases, infections, myelofibrosis, acute pancreatitis, psoriasis and ROHHAD (rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation). Read More
Genescience Pharmaceuticals Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα (H1047R mutant), reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum. Read More
Capsida Biotherapeutics Inc. presented preclinical data for a new next-generation gene supplementation therapy candidate, CAP-003, for Parkinson’s disease (PD) patients with GBA1 mutations (PD-GBA). Read More
Xi’an Xintong Medicine Research Co. Ltd. has described Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of cancer. Read More
Investigators from Microbiotix Inc. have published preclinical data for the novel spectinamide, MBX-4888A (Lee-1810), being developed for the treatment of tuberculosis (TB). Read More
